Yasmin Blood Clot Lawsuits Now Pending In Switzerland and France

Allegations that Bayer’s birth control pill Yasmin caused blood clots in young women are now pending in Switzerland and France.

The latest news comes from the Swiss where according to Reuters, Switzerland’s biggest health insurer CSS is supporting a young woman in her claim against Bayer, as the fall-out from alleged side effects of the German drugmaker’s contraceptive pill widens.

CSS said it supported its client in her claim against Bayer and is acting as a joint plaintiff. The health insurer is demanding payment from Bayer to cover medical costs.

Swiss media reported the young woman suffered from a pulmonary embolism, a blood clot in her lung, that left her severely disabled a few weeks after being prescribed the pill. The cost of medical treatment has amounted to some 600,000 Swiss francs ($648,600), according to reports.

A Bayer spokesman said the company could not comment on pending lawsuits but added the Yasmin group of pills had a positive risk-benefit profile based on extensive scientific data.  He also said the decision which contraceptive to take rests with the patient and her doctor.

Bayer has so far agreed to pay a combined $750 million to settle 3,490 legal claims in the United States that Yasmin caused blood clots, and such injuries are alleged in a further 3,800 pending U.S. cases.

U.S. health regulators have added warnings to the labels on the pills to show they may raise the risk of blood clots.

Revenues from the Yasmin group of birth-control pills, Bayer’s second-best selling pharmaceutical brand, are also in decline because of cheaper generic copies that are for sale in United States.

Bayer is already under fire in other markets over new-generation contraceptives.

In France a woman sued Bayer in mid-December, saying her stroke was caused by the contraceptive Méliane, a third-generation pill that contains gestodene, a form of progestin.

Therefore they are also acting on concerns that the pills carry a higher risk of blood clots than older birth-control brands, and France’s health ministry will stop paying for third-generation pills beginning March 31.

The French moves follow the FDA’s long-term review of some lower-dose contraceptives. After new studies suggested a higher risk of serious blood clots with birth-control pills containing drospirenone, the agency in 2011 asked an advisory committee to weigh the data. The committee backed the pills in a 15-11 vote but suggested a labeling update. Then, in April, the FDA added data on the pills’ clotting risks to their official labels.

Bayer maintains that its own research hasn’t turned up any additional risk with its newer pills when compared with older contraceptives.

You May Also Like


GET HELP NOW!

  • This field is for validation purposes and should be left unchanged.



, ,

No comments yet.

Leave a Reply

GET HELP NOW!
  • This field is for validation purposes and should be left unchanged.
Latest Drug Injury News

What Is Doribax?

According to the FDA the antibacterial drug Doribax, that has been used to treat patients who develop pneumonia on ventilators, carries an increased risk of death and has a lower clinical cure rate by injection compared a similar drug known as Primaxin. What is Doribax? Doribax is an antibiotic that fights serious infections caused by […]

Is Using Tylenol or Ibuprofen During Pregnancy linked to ADHD?

What is a mother to do if she becomes ill during pregnancy?  The risks of consuming common drugs when pregnant are complex.  Although many doctors assure mothers that taking Tylenol is safe, a recent study by JAMA Pediatrics suggests otherwise.  The study found that mothers who used Tylenol for fever reduction while pregnant reported greater […]

Paxil Linked To Breast Cancer

City of Hope Cancer researchers indicate that a new test called the AroER Tri-Screen, desgined to look for drug side effects that could cause cancer, found a potential link between Paxil and breast cancer.  Paxil is a widely prescribed anti depressant. Research Researchers have found that Paxil has a weak estrogen effect that could increase […]

What Is Stroke?

Have you or someone you know had a stroke?  Chances are…yes.  According to the CDC, stroke is the fourth leading cause of death in the United States. About 800,000 people in the U.S. have a stroke each year. What Is Stroke? Stroke occurs when a blood clot blocks an artery or a blood vessel breaks, […]

Paxil Possibly Linked To Breast Cancer Risk

Cancer researchers from the City of Hope National Medical Center announced a possible link between Paxil and breast cancer. Research focused on Paxil’s estrogen effect Researchers found that Paxil has a weak estrogen effect that could increase women’s breast cancer risks. According to lead author and chairman of City of Hope’s Department of Cancer and […]

Latest Medical Device Injury News

Report Raises Concerns Over Heart Defibrillator Leads

The Food and Drug Administration (FDA) has just announced that they received a report that a St. Jude Durata cardiac defibrillator lead conductor became externalized; meaning the wire carrying electricity from the heart defibrillator to the heart was exposed through its insulation, a potentially dangerous and life-threatening defect.

HeartSine Class 1 Defibrillator Recall

HeartSine sent out a letter to customers in September, warning that the defibrillators may intermittently turn on and off, eventually depleting the battery.

FDA Medical Device Approval Based On Little Evidence

More than half of the high-risk cardiovascular devices approved in the past decade had no supporting active control data.

St. Jude Medical Gets FDA Warning

St. Jude Medical Inc. said it received a FDA warning about manufacturing and quality-control problems at its Sylmar, California, plant.

Hospira Still Facing Manufacturing And Regulatory Issues

Hospira has sent out 11 device notifications so far in 2013, including recall and device corrections. The company also said it sent notices to customers about some of its infusion pumps that had to either be recalled, fixed or adjusted.